July 15, 2016

The Massachusetts Life Sciences Center and Massachusetts General Hospital launch the Massachusetts Center for Alzheimer Therapeutics Science (MassCATS)

The Massachusetts Life Sciences Center (MLSC), Massachusetts General Hospital (MGH) and five leading biopharma companies have launched the Massachusetts Center for Alzheimer Therapeutics Science (MassCATS), a unique collaboration among world-class industry and academic researchers working to find therapies for Alzheimer’s disease.  The new Center will be located at MGH.  Industry partners, including AbbVie, Biogen, Janssen Pharmaceuticals, Inc., Merck and Sunovion Pharmaceuticals have committed $1.25 million in Alzheimer’s-related research funding.

Read the press release here

MassCATS photo 1

(left to right).  Massachusetts Assistant Secretary for Economic Development Mike Kennealy, Alzheimer’s advocate and caregiver Brenda Bouchard, Massachusetts Secretary for Housing & Economic Development Jay Ash, Director of MA Alzheimer’s Disease Research Center Brad Hyman, Ph.D., Massachusetts General Hospital President & CEO Peter Slavin, Massachusetts Life Sciences Center General Counsel and VP for Academic & Workforce Programs Beth Nicklas, and Massachusetts Life Sciences Center President & CEO Travis McCready celebrate the launch of the new Massachusetts Center for Alzheimer Therapeutics Science (MassCATS) at Massachusetts General Hospital.
June 29, 2016

Eurofins Lancaster Laboratories expands Northeast footprint; opens first office in Cambridge, Mass.

Eurofins Lancaster Laboratories, a global leader in bio/pharmaceutical laboratory services, announced today the opening of its Northeast office, located in the Cambridge Innovation Center (CIC) in Cambridge, Massachusetts.

Backed by a 55-year successful track record, Eurofins Lancaster Laboratories offers a complete range of CMC Testing Services to support virtual and large bio/pharmaceutical companies and CMOs worldwide, including testing of all starting materials, process intermediates, bulk drug, finished product, and final packaging components through its broad technical expertise in Biochemistry, Molecular & Cell Biology, Virology, Chemistry and Microbiology.

Read the Press Release here

June 13, 2016

French-based ‘Live Biotherapeutic’ Company Biose to open their first US office in Cambridge

BIOSE®, a French pharmaceutical company, the Massachusetts Life Sciences Center, and MassBio announced that BIOSE® is opening their first US office in Cambridge, Massachusetts at the Cambridge Innovation Center.  BIOSE®’s mission is to design and market the best live biotherapeutic products to improve human health. Their Massachusetts office will primarily focus on licensing activities.

Read the Press Release here

IMG_20160607_134203

Maxence Desjonquères (far left), CEO of Biose, meets with Massachusetts life sciences and economic development leaders in the Massachusetts Pavilion at the BIO 2016 Convention in San Francisco, including (from left to right) Travis McCready, President & CEO of the Massachusetts Life Sciences Center, Lisa Hemmerle, Director of Economic Development for the City of Cambridge, Pamela Norton, Vice President for Industry Relations & Programs at the Massachusetts Life Sciences Center, and Jay Ash, Massachusetts Secretary for Housing & Economic Development.
June 8, 2016

Massachusetts Life Sciences Center announces Grant Program focused on attracting new companies

Massachusetts Transition and Growth Program (“MassTAG”) will provide grant funding to companies to help them establish operations in Massachusetts.

Read the Press Release Here

photo MassTAG

Photo Caption:

Massachusetts life sciences leaders announce the launch of the MLSC’s new MassTAG program at the 2016 BIO International Convention.  From left to right, Massachusetts Housing & Economic Development Secretary Jay Ash (at podium), MLSC President & CEO Travis McCready, MassBio President & CEO Bob Coughlin, Nanobiotix USA CEO Patrick Tricoli, City of Boston Chief of Economic Development John Barros, and Cambridge Economic Development Director Lisa Hemmerle.

May 26, 2016

Massachusetts Life Sciences Center announces $1.5 million in Accelerator loans for promising early-stage companies

The Massachusetts Life Sciences Center (MLSC) announced today the awarding of $1.5 million in Accelerator loan financing to two promising early-stage companies, Lexington-based MX Orthopedics Corp, and Bedford-based First Light Biosciences Inc.

Read the Press Release Here

MX Orthopedics Corp., Lexington – $750,000

  • MX Orthopedics Corp. is a medical device company focused on the development and commercialization of innovative and effective orthopedic devices such as compression staples, screws, plates and intramedullary implants, made from the shape memory alloy Nitinol.
  • Their dynaMX line of fraction fixation implants is designed to address a problem with existing fracture fixation devices; using Nitinol’s properties, these devices will be able to generate and maintain greater compression across the fracture site.
  • Funding from the MLSC will help MX Orthopedics move towards commercialization. MLSC funds will accelerate the filling of key positions to scale up the launch efforts. Funds will also enable the purchasing of inventory for their potential OEM distribution partner.

First Light Biosciences Inc., Bedford – $750,000

  • First Light is commercializing products for rapidly detecting and treating deadly hospital infections.
  • The company’s technology focuses on delivering affordable rapid tests to detect multiple types of hospital infections, including C-difficile, MERSA and urinary tract infections and identify the infectious agent causing them.
  • Their technology enables not only the identification of the pathogen, but also the identification of the optimal antibiotic to treat the patient. They intend to deliver this product at a cost similar to culturing.
  • First Light’s MultiPath platform is an automated bench top analyzer that expects to be able to accommodate a menu of application-specific cartridges.
  • A loan from the MLSC will help First Light Biosciences accelerate the commercialization of their initial consumable diagnostic testing product, and hire and support 3 assay development scientists to accomplish that objective and push forward to achieve FDA approval.
May 20, 2016

Massachusetts Life Sciences Center to Launch Capital Project Solicitations May 27 & May 31

The Massachusetts Life Sciences Center (MLSC) announced today that the agency will launch an open solicitation for life-sciences-related capital projects on May 27th, and an open solicitation for high school and middle school equipment & supply grants on May 31st. Funding for both programs was included in the Baker/Polito Administration’s capital plan that was released yesterday.  The Administration’s Fiscal Year 2017 capital plan provides $63.6 million for the Massachusetts Life Sciences Center, a 15% increase over the Center’s projected spending of $55 million in FY16.

Read the Press Release Here

May 19, 2016

Life Sciences High School Apprenticeship Training Program Graduates First Class of Students

The Massachusetts Life Sciences Center and the BioBuilder Educational Foundation held their first-ever graduation ceremony for Life Sciences High School Apprentices at LabCentral in Cambridge. Twenty-seven students from Boston and Cambridge have successfully completed an eight-week lab-readiness training program as part of the newly established Life Sciences High School Apprenticeship Challenge training program, the pilot year of which was funded by a $50,000 grant from the Massachusetts Life Sciences Center (MLSC).

Read the Press Release Here»

Apprenticeship graduation photo

Massachusetts Life Sciences Center President & CEO Travis McCready congratulates one of the graduates of the Life Sciences High School Apprenticeship Challenge training program
April 28, 2016

Web Industries Opens New Lateral Flow Immunoassay (LFI) Manufacturing Facility

Web Industries, Inc., innovative provider of precision contract manufacturing and converting services, is proud to announce the opening of the company’s first lateral flow immunoassay (LFI) production facility. Co-located within the company’s existing Web Boston location, the Lateral Flow Diagnostics Center of Excellence will provide companies marketing LFI tests with a one-stop outsource manufacturing solution that offers a reliable path from small-scale test development to high-volume commercialization of new LFI devices. The 6,500 square foot environmentally-controlled facility was purpose-built for automated reel-to-reel medical device production and features an in-house biochemistry lab, reagent deposition, LFI strip manufacturing, device assembly, and packaging stations.

Read the press release here »

IMG_0481
From left to right Dennis Latimer, Executive Vice President of Strategy and M&A, Blake Batley, Chief Sales & Marketing Officer, Mark Pihl, President & Chief Operating Officer, Don Romine, Chief Executive Officer, and Jon Nuñez, Chief Financial Officer cut a ribbon to celebrate the Lateral Flow Diagnostics Center of Excellence in Holliston, MA.
April 27, 2016

Baker-Polito Administration Awards Job Creation Incentives to 28 Life Science Companies

The Baker-Polito Administration announced $20 million in tax incentive awards, to 28 life sciences companies. The awards, which will create 1,325 new jobs in the Commonwealth in 2016, were approved today by the Board of Directors of the Massachusetts Life Sciences Center (MLSC). The tax incentive awards will support life sciences job growth in fourteen Massachusetts cities and towns; half of the awardees are located or are expanding outside of Greater Boston.

Read the press release here »

Company Location Incentive Amount Jobs
908 Devices Inc. Boston $165,000 11
AbbVie Inc. Worcester $525,000 35
Abiomed, Inc. Danvers $1,050,000 70
Alnylam Pharmaceuticals, Inc. Cambridge $2,250,000 150
Amgen Inc. Cambridge $780,000 52
Baxalta US, Inc. Cambridge $1,320,000 66
Charles River Laboratories, Inc. Wilmington $1,200,000 80
Emulate, Inc. Boston $318,090 30
Enanta Pharmaceuticals, Inc. Watertown $360,000 24
Ginkgo Bioworks, Inc. Boston $483,377 50
Juno Therapeutics, Inc. Waltham $165,000 11
LFB USA, Inc. Framingham $720,000 48
Masy Systems, Inc. Pepperell $150,000 10
Merrimack Pharmaceuticals, Inc. Cambridge $225,000 15
Moderna Therapeutics, Inc. Cambridge $1,875,000 125
Nitto Denko Avecia Inc. Milford $450,000 30
Nova Biomedical Corporation Waltham $750,000 50
Pharmalucence, Inc. Billerica $150,000 10
Quanterix Corporation Lexington $225,000 15
Radius Health, Inc. Waltham $525,000 35
Sarepta Therapeutics, Inc. Cambridge $750,000 50
Seres Therapeutics, Inc. Cambridge $945,000 63
Shire Human Genetic Therapies, Inc. Lexington $2,250,000 150
Siemens Healthcare Diagnostics, Inc. Walpole $735,000 30
SQZ Biotechnologies Company Boston $129,784 20
STC Biologics, Inc. Cambridge $150,000 10
Takeda Pharmaceuticals America, Inc. Cambridge $1,125,000 75
Web Industries Boston, Inc. Holliston $150,000 10

 

April 25, 2016

Regis College enhances science learning with opening of newly renovated science laboratory

Regis College announced the opening of their newly renovated life science training facility. This more than 800 square-foot science laboratory, enhanced with new state-of-the-art scientific equipment, was enabled by a $355,000 capital grant from the MLSC.  This facility will position Regis College to better prepare students for careers in the life sciences.

Regis College 2

From Left to right  Antoinette Hays, PhD, RN, Regis College President, Diana Tran, Regis College Student and President & CEO of the Massachusetts Life Sciences Center Travis McCready cut a ribbon to celebrate the opening of the college’s newly renovated life sciences training facility.

Read the press release here »

April 19, 2016

Anagenesis Biotechnologies launches its US subsidiary, Anagenesis Biotherapies Inc. in Boston, Massachusetts to carry out its cell therapy programs

Anagenesis Biotechnologies, a company developing stem cell-derived treatments for muscle diseases, announced the creation of its US subsidiary, Anagenesis Biotherapies Inc. with offices at the Cambridge Innovation Center’s 50 Milk Street facility in Boston, Massachusetts. The US subsidiary will carry out the company’s cell therapy programs with an initial focus on Duchenne Muscular Dystrophy (DMD), paving the way for future partnerships.

Read the press release here »

April 11, 2016

CeQur Initiates Significant Facility Expansion in Marlborough

CeQur® announced that the company is doubling the size of its Marlborough facilities in preparation for the launch of PAQ®, the company’s simple, three-day insulin infusion device. When completed later this year, the Marlborough facility will total 25,000 square feet, including a new clean room, labs and a manufacturing line. CeQur anticipates the expanded space will house 150 employees – the company’s 50 current employees, in addition to more than 100 employees CeQur plans to hire over the next 24 months.

CeQur wall breaking photo 4.11.16

CeQur CEO Doug Lawrence (with hammer) is joined by local and state officials at the company’s wall-breaking ceremony today in Marlborough.  Participants included Marlborough Mayor Arthur Vigeant (second from left), CeQur Senior VP of Commercialization Jay Warner (third from left), MLSC President& CEO Travis McCready (fourth from left), State Representative Danielle Gregoire (center), and MassMEDIC President Tom Sommer (second from right).

Read the press release here »

March 22, 2016

Affera Inc. Expands with New Office in Watertown

Affera has announced its move to a larger facility on 44 Pleasant Street, along the Charles River in Watertown. Affera is a venture-backed medical device company founded by a seasoned team of industry leaders. The company is developing an innovative system for the treatment of heart rhythm disorders, one of the fastest growing fields in medical devices.

Read the press release here »

March 1, 2016

Massachusetts Life Sciences Center Announces Launch of 2016-17 Internship Challenge

The Massachusetts Life Sciences Center (MLSC) announced the launch of the 2016-17 Internship Challenge program.  This year’s program will feature a $700,000 increase in funding, an increase in the maximum reimbursable pay rate for interns from $15/hour to $17/hour, and a new incentive for long-term hiring by participating companies.  Under the new hiring incentive companies that offer a long-term position to a participating intern will be able to receive funding for a replacement intern.

Read the press release here »

February 24, 2016

Swiss life sciences company Biognosys to open an office in Boston area

Biognosys, a Swiss next-gen proteomics company announced that it will open its new North American office in Greater Boston, Massachusetts in Q2 this year. The office will be the firm’s first North American location. The Massachusetts Life Sciences Center has worked closely with Biognosys on their location selection decision.

Read the press release here »

Connect With Us

Facebook LinkedIn Twitter